Lupus Nephritis: Novel Treatments and Diagnostic Approaches

被引:0
|
作者
Jain N.G. [1 ,3 ]
Hunt E.A.K. [1 ,3 ]
Paul E. [2 ,3 ]
Somers M.J.G. [1 ,3 ]
机构
[1] Division of Nephrology, Boston Children’s Hospital, 300 Longwood Avenue, Boston
[2] Division of Pediatric Nephrology, MassGeneral Hospital for Children, Boston, MA
[3] Department of Pediatrics, Harvard Medical School, Boston, MA
关键词
Belimumab; Cyclosporine (CSA); IVCY; Lupus nephritis; MMF; Rituximab; Systemic lupus erythematous (SLE);
D O I
10.1007/s40124-012-0005-1
中图分类号
学科分类号
摘要
Over the last decade, therapy for lupus nephritis in children has begun to shift from the provision of long-term steroids and intravenous cyclophosphamide to regimens with limited or no cyclophosphamide, lower steroid burdens, and increased reliance on oral mycophenolate mofetil. As the molecular immunology underlying the pathophysiology of lupus is further discerned, more targeted therapies, including the use of monoclonal antibodies against immune cells or cell signaling factors, may come to play a larger role in the treatment of pediatric lupus. Similarly, as experience with autologous stem cell transplantation for therapy-resistant disease is gained in adults, its potential applicability to such situations in children may be clarified. Over the next few decades, children with lupus will benefit as well from the identification of new biomarkers that are both sensitive and specific to disease activity, allowing clinicians to more readily assess response to therapy and diagnose disease flare. © 2012, Springer Science + Business Media New York.
引用
收藏
页码:41 / 51
页数:10
相关论文
共 50 条
  • [41] Novel Biomarkers for Lupus Nephritis in the "OMICS" Era
    Dias, Raphael
    Hasparyk, Ursula Gramiscelli
    Lopes, Monisi Peres
    de Barros, Joao Luiz Vieira Monteiro
    Simoes e Silva, Ana Cristina
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (29) : 6011 - 6044
  • [42] HEPARANASE AS A NOVEL MARKER OF LUPUS NEPHRITIS ACTIVITY
    Szymczak, Maciej
    Kuzniar, Jakub
    Kopec, Waclaw
    Marchewka, Zofia
    Klinger, Marian
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 182 - 183
  • [43] Lupus Nephritis: The Evolving Role of Novel Therapeutics
    Rovin, Brad H.
    Parikh, Samir V.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (04) : 677 - 690
  • [44] Peroxidasin Is a Novel Target of Autoantibodies in Lupus Nephritis
    Manral, Pallavi
    Colon, Selene
    Bhave, Gautam
    Zhao, Ming-Hui
    Jain, Sanjay
    Borza, Dorin-Bogdan
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (07): : 1004 - 1006
  • [45] Novel and emerging treatment strategies for lupus nephritis
    Yap, Desmond Yat Hin
    Mok, Chi Chiu
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (11) : 1283 - 1292
  • [46] Urinary Angiostatin As a Novel Biomarker in Lupus Nephritis
    Wu, Tianfu
    Xie, Chun
    Han, Jie
    Mohan, Chandra
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S650 - S651
  • [47] LUPUS TUBULOINTERSTITIAL NEPHRITIS: THE FORGOTTEN LUPUS NEPHRITIS
    Liang, Kelly
    Adomako, Emmanuel
    Fields, Timothy
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [48] Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?
    Boumpas, DT
    Sidiropoulos, P
    Bertsias, G
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2005, 1 (01): : 22 - 30
  • [49] Unraveling the podocyte injury in lupus nephritis: Clinical and experimental approaches
    dos Santos, Mariane
    Poletti, Priscila Tamar
    Milhoransa, Patricia
    Monticielo, Odirlei Andre
    Veronese, Francisco Verissimo
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 46 (05) : 632 - 641
  • [50] QUANTITATIVE PROTEOMIC APPROACHES FOR IDENTIFYING URINARY BIOMARKERS IN LUPUS NEPHRITIS
    Anania, V. G.
    Cascino, M.
    Dragone, L. L.
    Looney, C.
    Rae, J.
    Liu, P.
    Sandoval, W.
    Katsumoto, T. R.
    Neighbors, M.
    Morimoto, A.
    Herman, A. E.
    Mathews, W. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 950 - 950